Abstract
Mammarenaviruses cause chronic infections in rodents, which are their predominant natural hosts. Human infection with some of these viruses causes high-consequence disease, posing significant issues in public health. Currently, no FDA-licensed mammarenavirus vaccines are available, and anti-mammarenavirus drugs are limited to an off-label use of ribavirin, which is only partially efficacious and associated with severe side effects. Dihydroorotate dehydrogenase (DHODH) inhibitors, which block de novo pyrimidine biosynthesis, have antiviral activity against viruses from different families, including Arenaviridae, the taxonomic home of mammarenaviruses. Here, we evaluate five novel DHODH inhibitors for their antiviral activity against mammarenaviruses. All tested DHODH inhibitors were potently active against lymphocytic choriomeningitis virus (LCMV) (half-maximal effective concentrations [EC50] in the low nanomolar range, selectivity index [SI] > 1000). The tested DHODH inhibitors did not affect virion cell entry or budding, but rather interfered with viral RNA synthesis. This interference resulted in a potent interferon-independent inhibition of mammarenavirus multiplication in vitro, including the highly virulent Lassa and Junín viruses.
Funder
Battelle Memorial Institute
National Institute of Allergy and Infectious Diseases
Subject
Virology,Infectious Diseases
Reference54 articles.
1. Arenavirus quasispecies and their biological implications;Grande-Pérez;Curr. Top. Microbiol. Immunol.,2016
2. Lassa fever diagnostics: past, present, and future
3. Emerging infectious diseases and risk to the traveler;Freedman;Med. Clin. N. Am.,1999
4. Viral Hemorrhagic Fever Hazards for Travelers in Africa
5. Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献